Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
Stock Of The Day: Where Does The Merck Downtrend End?
11:54am, Thursday, 19'th Dec 2024
Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
09:26am, Thursday, 19'th Dec 2024
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Dow Losing Streak Longest in 50 Years: Grab These Bargain Blue-Chip Dividend Stocks Now
08:46am, Thursday, 19'th Dec 2024
The Dow Jones industrial average is a price-weighted index of 30 blue-chip U.S.
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
08:32am, Thursday, 19'th Dec 2024
Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines, with strong revenue from Keytruda and Gardasil despite challenges in China. Strategic acquisitions and partn
Merck's HIV treatment meets main goal of two late-stage studies
06:59am, Thursday, 19'th Dec 2024
Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Topline Results from Phase 3 Trials Evaluating Once-Daily, Oral Doravirine/Islatravir for the Treatment of Adults with HIV-1 Infection.
Merck's weight-loss pill deal: what it means for Eli Lilly
12:02pm, Wednesday, 18'th Dec 2024
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral)
Merck pens $2bn deal for obesity drug from China's Hansoh
11:28am, Wednesday, 18'th Dec 2024
Merck & Co Inc (NYSE:MRK, ETR:6MK) has sought a potential weight loss drug candidate through a deal worth up to $2 billion with China's Hansoh Pharma. US-based Merck will get exclusive rights to devel
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
11:00am, Wednesday, 18'th Dec 2024
The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
Merck to End Development of Two Cancer Candidates: Time to Sell?
10:51am, Wednesday, 18'th Dec 2024
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
10:25am, Wednesday, 18'th Dec 2024
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk's dominance in the weight-loss market.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
07:59am, Wednesday, 18'th Dec 2024
Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million upfront
Merck signs up to $2 bln obesity drug deal with Chinese biotech Hansoh
06:59am, Wednesday, 18'th Dec 2024
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug.
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
06:45am, Wednesday, 18'th Dec 2024
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered i
Barclays fact-checked Trump comments on pharmacy benefit managers
01:40pm, Tuesday, 17'th Dec 2024
Barclays analyst Andrew Mok said that while the existential risk to pharmacy benefit managers is low, President-elect Trump's comments yesterday point to additional headline risk and greater support f
